ONC: BeiGene Ltd Net earnings per share (EPS TTM)
Geopolitical pressure and testing costs create risks for BeiGene Ltd (ONC), as confirmed by the fundamental EPS TTM metric, where the value remains at 7.89. BeiGene Ltd (ONC) is implementing targeted therapy to reduce treatment toxicity. Meanwhile, high margins in the West are offset by strict government price regulations in China, which limit business profitability.
Metric breakdowns and analytics for BeiGene Corp (ONC)
- current quotes and average value forecast:
- market capitalization information:
- business book valuation details:
- debt and liquidity details:
- net income and valuation multiples indicators:
ONC - Company Net Income|Future Profit BeiGene Ltd|ONC - Company Value to Net Income|Future Price to Earnings BeiGene Corp|ONC - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio BeiGene Ltd|ONC - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) BeiGene|ONC - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months beigene.com|ONC - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year BeiGene Ltd
- sales and revenue indicators:
Comprehensive company analysis:BeiGene Oncology (ONC)
This metric determines the portion of the final financial result attributable to a single common share by dividing the total annual profit by the total number of securities. By analyzing the net income per share over a rolling 12-month period, an investor can see how the expansion of Brukinsa and the launch of new therapies translate into actual return on capital against the backdrop of massive R&D expenditures for BeiGene Ltd (ONC).
Main competitors
HALO: Net earnings per share for the last 12 months|RVMD - Net earnings per share (EPS TTM)|Ascentage (AAPG) - Earnings per share for the last twelve months|CG Oncology Corp - Earnings per share for the trailing year|URGN (UroGen Pharma Ltd) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Bicara Therapeutics Inc. BCAX|Earnings per share for the last twelve months Personalis, Inc. (PSNL)|ERAS - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) DCTH (delcath.com)|Net earnings per share for the trailing year Y-mAbs Corp|AURA - Earnings per share for the last twelve months|CADL (candeltx.com) - Earnings per share for the last 12 months|ARAY (accuray.com) - Net earnings per share for the last 12 months|SELLAS Life Sciences Group Inc. (SLS) - Net earnings per share (EPS TTM)|ACTU (Actuate Therapeutics Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Citius Oncology Inc|Net earnings per share (EPS TTM) HURA|TARA (Protara Therapeutics) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) FATE (Fate Therapeutics)|Net earnings per share for the last four quarters Aadi Bioscience Inc (WHWK)|TScan Therapeutics, Inc. - Net earnings per share (EPS TTM)|CSBR (Champions Oncology, Inc.) - Earnings per share for the last 12 months|XBIT (XBiotech USA) - Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months CEL-SCI Corp (CVM)|OSTX (OS Therapies Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Radiopharm Theranostics (RADX)|Net earnings per share for the last 12 months ARTV (Artiva Biotherapeutics, Inc.)|ANL - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Veru Inc. VERU|Earnings per share for the trailing year TPST|XLO: Net earnings per share for the last 12 months|Net earnings per share for the last four quarters Renovaro RENB|MURA (muraloncology.com) - Net earnings per share for the last 12 months|Kairos Pharma Inc - Earnings per share for the trailing year|Net earnings per share for the last 12 months OKUR|Net earnings per one share for the last twelve months CytoMed Therapeutics Limited GDTC|Net earnings per share (EPS TTM) CRIS|Net earnings per share (EPS TTM) Apollomics Inc. (APLM)|Net earnings per share (EPS TTM) THAR (Tharimmune Corp)|Net earnings per share for the last four quarters Advanced Biomed Inc (ADVB)|Genprex Inc - Net earnings per share (EPS TTM)|CLDI - Net earnings per share (EPS TTM)|Sunshine Biopharma Inc. (SBFM) - Earnings per share for the last twelve months|XBIO - Net earnings per share for the last four quarters|SLRX (Salarius Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Kitov Pharma|Net earnings per share for the last 12 months AONC (American Oncology Network)|BGNE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CKPT (Checkpoint Therapeutics Inc.)|Elevation Oncology, Inc. - Earnings per share for the last twelve months|ICAD - Earnings per share for the last twelve months|IKNA - Net earnings per share (EPS TTM)|Notable Labs (NTBL) - Earnings per share for the last twelve months|Earnings per share for the last 12 months VIRX|MOR (MorphoSys Corporation) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NAYA Biosciences Inc NAYA|Earnings per share for the last twelve months Ascentage Pharma (AAPGV)
